Skip to content

Human Milk and Infant Intestinal Microbiome Study

Human Milk and Infant Intestinal Microbiome Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03181269
Enrollment
6
Registered
2017-06-08
Start date
2017-07-27
Completion date
2018-12-20
Last updated
2018-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding, Human Microbiome

Brief summary

This study will explore the effects of skin-to-skin contact (SSC) between mothers and their babies on the infant intestinal microbiome, the maternal skin microbiome and the breast milk microbiome. This will be accomplished by administering an intervention education session to one group and a placebo education session to the second group in order to influence the magnitude of total SSC defined by the frequency and duration of contact time between the two groups.

Interventions

OTHERIntervention education

An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.

OTHERPlacebo Education

An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Pregnant women scheduled to deliver at the University of Virginia Health System * Women 18 years or older and their newborn infant * Stated intent to exclusively breastfeed for the duration of post-partum hospital admission * To have physical custody of their child when they are discharged from the hospital

Exclusion criteria

* Maternal antibiotic use in the 3 months prior to delivery * Consumption of alcohol in the 3 months prior to delivery * Recreational drug use in the 3 months prior to delivery * Serious gastrointestinal conditions requiring medical intervention or medication during pregnancy (e.g. Crohn's disease, ulcerative colitis, celiac disease, gastrointestinal infections) * Serious health conditions that require medication during pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Skin-to-skin contactDuration of hospital admission after delivery (2-3 days)Self-reported magnitude of maternal-infant skin-to-skin contact

Secondary

MeasureTime frameDescription
Maternal skin microbiomeDuration of hospital admission after delivery (2-3 days)Maternal breast area skin microbiome
Maternal breast milk microbiomeDuration of hospital admission after delivery (2-3 days)Maternal first and early milk microbiome
Infant intestinal microbiomeDuration of hospital admission after delivery (2-3 days)Infant fecal microbiome
Maternal dietary intakeDuring pregnancyMaternal dietary intake of probiotic or culture-enhanced foods

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026